A company developing medicines that silence genes brought in about $230 million before costs.
City Therapeutics, a biotech company, raised $230 million in its upsized IPO, selling 12.78 million shares at $18 each. The company's stock began trading on Nasdaq under the ticker CTY. City Therapeutics focuses on RNA interference therapeutics for diseases like thromboembolic conditions and retinal diseases.
How this was made
The 30-second read
Why it matters
The capital raise strengthens the balance sheet for pipeline advancement, while market debut creates liquidity and price discovery.
Market read
First report of a sizable biotech IPO, introducing a new ticker and capital to the market.
What to watch
Regulatory milestones and trial outcomes will drive long‑term performance
Background
City Therapeutics is a clinical‑stage biotech focused on RNA interference therapeutics, launching its Nasdaq ticker CTY after an upsized public offering.
Ticker impact
City Therapeutics disclosed the closing of its upsized IPO, raising roughly $230 million and beginning trading on Nasdaq.
upward pressure as investors price in the new capital and growth potential
First‑day trading typically sees buying interest for biotech IPOs, especially with a sizable raise and Nasdaq listing.
Market effects
Adds a new listed biotech to the RNAi therapeutic space, may boost sector interest
Positive for US biotech listings, modest effect on broader Nasdaq
Limited to investors tracking biotech IPOs and RNAi platforms
Counterpoint
Potential overvaluation risk for a clinical‑stage biotech without revenue
Key entities
- companyCity Therapeutics, Inc.
Clinical‑stage biotech developing RNAi therapeutics, ticker CTY
- underwriterGoldman Sachs & Co. LLC
Joint book‑running manager for the IPO
